Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Blastocyst development in vitro compared with basal serum AMH and selected clinical/embryology parameters among IVF patients (n = 79)

From: Bivariate analysis of basal serum anti-Müllerian hormone measurements and human blastocyst development after IVF

  No blastocyst
(n= 46)
Blastocyst
(n= 33)
Difference
(95% CI)
p 1
Serum AMH (pmol/l) 10.9 (3.6, 19.5) 15.6 (10.7, 22.9) 4.9 (0.6 to 8.9) 0.029
Age (yrs) 35.9 (33.5, 39.2) 37.3 (33.7, 40.3) 0.7 (-1.4 to 2.7) 0.509
Terminal E2 (pmol/l) 4084 (2996, 5164) 7282 (3572, 10770) 2335 (-260 to 6361) 0.121
Oocytes retrieved (total n) 7 (4, 17) 10 (7, 13) 3 (1, 5) 0.004
MII oocytes retrieved (n) 5 (3, 8) 9 (6, 12) 3 (2, 5) 0.006
Early cleavage embryos (n) 3.5 (2, 6) 6 (5, 9) 3 (2, 4) 0.002
≥7-cell embryos on d3 (n) 1.5 (0, 3) 2 (1, 4) 1 (0, 2) 0.07
  1. 1by Mann-Whitney U test
  2. Notes: All data presented as mean (IQR 25,75); AMH = anti-Müllerian hormone; E2 = estradiol;
  3. MII = metaphase II; d3 = post-fertilisation day three